Heidi Anne Duerr

3 weeks ago | psychiatrictimes.com | Heidi Anne Duerr |Laxminarayan Bhat

Reviva Pharmaceuticals announced positive results from their phase 3 RECOVER open label extension of brilaroxazine (RP5063) for patients with schizophrenia.1,2 The trial looked at long-term safety, tolerability, and efficacy of once daily brilaroxazine over a 1-year period.

1 month ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REPORTERFor clinicians, researchers, and educators dedicated to improving outcomes in serious mental illness, the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting is more than just a professional gathering, it is a dynamic forum where innovation meets application, Joseph F. Goldberg, MD, told Psychiatric Times in an exclusive interview.

1 month ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REPORTERNew data presented at the 2025 American Psychiatric Association Annual Meeting demonstrated that zuranolone was relatively safe and effective to addressing anhedonia in adult patients with postpartum depression (PPD).

1 month ago | psychiatrictimes.com | Joe Feldman |Heidi Anne Duerr

CONFERENCE REPORTERA new nonprofit organization is supporting clinicians and patients in their fight for mental health coverage. In an interview with Psychiatric Times at the 2025 American Psychiatric Association Annual Meeting, Joe Feldman, president of Cover My Mental Health, referred to the current crisis in mental health and the frustrating and sometimes seemingly futile attempts to ensure appropriate evidence-based mental health care for patients is covered by insurance.

1 month ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REEPORTER Researchers presented promising data for CPL’36, a phosphodiesterase 10A (PDE10A) inhibitor intended to treat acute schizophrenia exacerbation at the 2025 American Psychiatric Association (APA) Annual Meeting in Los Angeles, California.1 Jazwiec et al presented data from a double-blind, randomized, placebo controlled, parallel group phase 2 study (NCT05278156).2 The dose ranging study was designed to investigate the efficacy, safety, tolerability and pharmacokinetics...